Published in Nat Immunol on June 08, 2003
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity (2009) 3.18
PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev (2008) 2.40
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell (2016) 2.10
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci U S A (2005) 2.00
Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood (2012) 1.95
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2013) 1.84
SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev (2009) 1.78
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci U S A (2005) 1.76
Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol (2004) 1.72
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med (2008) 1.67
The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol (2012) 1.66
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther (2014) 1.58
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol Rev (2008) 1.49
Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci U S A (2009) 1.49
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis. PLoS One (2016) 1.38
DC-HIL is a negative regulator of T lymphocyte activation. Blood (2007) 1.37
Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol (2011) 1.36
Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer (2014) 1.35
Cell surface signaling molecules in the control of immune responses: a tide model. Immunity (2011) 1.32
The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med (2014) 1.30
T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev (2009) 1.30
An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol (2010) 1.30
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res (2015) 1.29
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol Rev (2011) 1.27
The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol (2009) 1.23
The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol (2008) 1.23
BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol (2012) 1.22
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget (2015) 1.20
Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology (2013) 1.19
Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol Cell Biol (2006) 1.18
B and T lymphocyte attenuator tempers early infection immunity. J Immunol (2009) 1.18
Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum (2008) 1.18
The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence (2013) 1.15
Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J Leukoc Biol (2010) 1.15
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis (2015) 1.15
The quantal theory of how the immune system discriminates between "self and non-self" Med Immunol (2004) 1.13
T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. J Immunol (2009) 1.11
Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol (2009) 1.10
Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood (2011) 1.10
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition. J Virol (2010) 1.07
Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system. Arthritis Res Ther (2003) 1.05
Real-time imaging of notch activation with a luciferase complementation-based reporter. Sci Signal (2011) 1.05
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med (2009) 1.03
B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients. Crit Care (2013) 1.03
Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med (2010) 1.03
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators. Front Immunol (2015) 1.01
Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations. J Exp Med (2011) 1.01
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther (2011) 1.00
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest (2009) 1.00
SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest (2013) 1.00
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells. Mol Med (2010) 0.98
CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA. PLoS One (2013) 0.96
Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol (2009) 0.96
The role of coinhibitory signaling pathways in transplantation and tolerance. Front Immunol (2012) 0.95
B and T lymphocyte attenuator regulates T cell survival in the lung. J Immunol (2008) 0.95
Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol (2013) 0.94
Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia. Haematologica (2014) 0.92
B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. J Infect Dis (2011) 0.92
B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells. Proc Natl Acad Sci U S A (2013) 0.91
The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease. Immunology (2013) 0.91
The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol (2013) 0.91
Costimulatory pathways in transplantation. Semin Immunol (2011) 0.90
Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol (2007) 0.90
Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol Cell Biol (2010) 0.90
The role of ICOS and other costimulatory molecules in allergy and asthma. Springer Semin Immunopathol (2004) 0.90
BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection. PLoS One (2013) 0.90
Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity. Eur J Immunol (2011) 0.89
B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. J Virol (2012) 0.89
The role of the T follicular helper cells in allergic disease. Cell Mol Immunol (2012) 0.89
Coinhibitory molecules in autoimmune diseases. Clin Dev Immunol (2012) 0.88
CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. J Immunol (2013) 0.88
New battlefields for costimulation. J Exp Med (2006) 0.88
Biomarkers for Sepsis: What Is and What Might Be? Biomark Insights (2015) 0.87
Pathogenic CD8+ T cells in experimental cerebral malaria. Semin Immunopathol (2015) 0.87
Transplantation tolerance and its outcome during infections and inflammation. Immunol Rev (2014) 0.86
The Relationship between B7-H4 Expression and Clinicopathological Characteristics in Clinical Stage T1 Conventional Renal Cell Carcinoma. Korean J Urol (2011) 0.86
The LIGHT and DARC sides of herpesvirus entry mediator. Proc Natl Acad Sci U S A (2005) 0.86
Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells. J Leukoc Biol (2009) 0.86
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Nat Immunol (2002) 7.28
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 6.94
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J Exp Med (2010) 4.56
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature (2008) 4.28
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature (2009) 3.75
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol (2004) 3.49
Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Reson Med (2007) 3.40
Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol (2007) 3.25
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol (2011) 3.21
Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 3.18
Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity (2012) 3.18
A distal conserved sequence element controls Ifng gene expression by T cells and NK cells. Immunity (2006) 3.16
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol (2004) 2.90
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 2.83
Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm. Development (2006) 2.82
Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol (2011) 2.80
Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 2.78
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76
Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J Exp Med (2012) 2.74
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity (2009) 2.61
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature (2005) 2.58
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol (2002) 2.54
CD8α(+) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites. Immunity (2011) 2.50
Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. Cell Stem Cell (2008) 2.46
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol (2002) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science (2012) 2.30
Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature (2012) 2.25
Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol Dis (2005) 2.25
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity (2004) 2.21
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med (2010) 2.20
Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature (2008) 2.18
Re(de)fining the dendritic cell lineage. Nat Immunol (2012) 2.17
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med (2007) 2.08
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev (2008) 2.08